Publications Search

 
 


Health & Life Sciences

RSS Feed

Repeal of s51(3) of the Competition and Consumer Act 2010 (Cth): It might be time to think about your competition - May 2019

On and from 12 September 2019, businesses that license or assign IP rights will be subject to the full application of anti-competition provisions under the Competition and Consumer Act regardless of whether those arrangements were entered into before or after that date.

Partner, Tim Clark, Associate, Philip Chow and Lawyer, Jamin Li, explain why businesses involved in the conditional licensing or assignment of IP rights should consider reviewing their current arrangements.

ACCC v Pfizer – Judgment summary and ramifications - Feb 2015

On 25 February 2015, Justice Flick of the Federal Court of Australia ruled in favour of Pfizer Australia Pty Ltd (Pfizer), dismissing the Australian Competition and Consumer Commission (the ACCC)’s case that Pfizer’s sales and marketing conduct immediately prior to the expiration of its Lipitor patent breached sections 46 and 47 of the Competition and Consumer Act 2010 (the CCA).

Legal Rx - Sep 2012

Welcome to the latest edition of Piper Alderman's Health and Life Sciences Update, Legal Rx.

In the September 2012 edition:

  • How logical is the regulation of Biologicals?
  • The Raising the Bar Act - Improving Australia's Intellectual Property Regime
  • Managing your risks under global anti-corruption regimes
  • Workplace bullying - what employers need to know

Health & Life Sciences Update - Legal Rx - Nov 2011

Welcome to the latest edition of Piper Alderman's Health & Life Sciences Update, Legal Rx.

In the November 2011 edition:

  • Full Federal Court upholds Merck's appeal in the VIOXX Representative Proceeding
  • Pharmaceutical company involvement in patient support programs - is it above board?
  • SPECIAL FEATURE - Social Media's place in the Pharmaceutical Industry
  • Did you know... 
 

Legal Rx Alert - Jul 2011

Welcome to this special Legal Rx Alert.

Government administration of the Pharmaceutical Benefits Scheme has come under significant public scrutiny, highlighting the lack of transparency in the overall process. Dr Teresa Schafer discusses some of the key issue that this raises for the pharmaceutical sector in Australia

Health and Life Sciences Update - Legal Rx - Jun 2011

Welcome to the latest edition of Piper Alderman's Health and Life Sciences update, Legal Rx.

In the June 2011 edition:

  • The patentability of biological material - Summary of public submissions to Senate inquiry
  • Regulation and PBS pricing of biosimilar drugs
  • What information can be submitted in applications for review of decisions by the Therapeutic Goods Administration?
  • Operation of the data exclusivity regime in Australia
  • Snapshots
 

Health and Life Sciences Update - Legal Rx - Feb 2011

Welcome to the latest edition of Piper Alderman's Health and Life Sciences Update, Legal Rx.

In the February 2011 edition:

  • The public debate about the patentability of biological material - Is it much ado about nothing?
  • Matters to consider when raising capital
  • The ongoing confusion about the concept of interchangeability
  • Responding to a hostile takeover bid
 
Found 7 Results, displaying 1 to 7